Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
NCT ID: NCT00872391
Last Updated: 2009-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
155 participants
INTERVENTIONAL
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypofractionated LINAC radiotherapy
Hypofractionated linear accelerator radiotherapy
10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hypofractionated linear accelerator radiotherapy
10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if the central tumor distance to the optic disc and/or the macula is 3 mm or less.
* If other forms of conservative treatment of the melanoma are not possible.
Exclusion Criteria
* Extrascleral tumor extension is present.
* If the presence of neovascular glaucoma is detected before treatment.
* If metastasis is detected at baseline.
* Previous participation in any study of investigational drugs within 3 month preceding day 0.
* Pregnant women are not allowed to participate in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical University of Vienna
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Zehetmayer, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Ophthalmology, Medical University of Vienna, Austria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology and the Department of Radiotherapy and Radiobiology, Medical University of Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Martin Zehetmayer, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK 017/2009
Identifier Type: -
Identifier Source: org_study_id